Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue
Total revenue	$ 913,444	$ 469,745
Operating expenses
Cost of products sold	592,378	291,997
Cost of services	128,306	30,562
Research and development, net	1,812,831	2,316,441
General and administrative	2,423,953	2,625,053
Sales and marketing	1,026,087	1,051,432
Total operating expenses	5,983,555	6,315,485
Operating loss	(5,070,111)	(5,845,740)
Other (expense) income
Interest and other income	30,106	3,121
Interest expense	(617,298)	(1,269,581)
Foreign currency transaction (losses) gains	(91,994)	198,740
Change in fair value of derivative financial instruments	12,694	109,744
Total other expense	(666,492)	(957,976)
Loss before income taxes	(5,736,603)	(6,803,716)
Provision for income taxes
Net loss	(5,736,603)	(6,803,716)
Net loss available to common stockholders	$ (5,736,603)	$ (6,803,716)
Basic and diluted net loss per share attributable to common stockholders (in Dollars per share)	$ (1.25)	$ (2.93)
Weighted average shares outstanding - basic and diluted (in Shares)	4,577,269	2,324,184
Net loss	$ (5,736,603)	$ (6,803,716)
Other comprehensive income (loss) - foreign currency translation	153,067	(483,849)
Comprehensive loss	(5,583,536)	(7,287,565)
Product sales
Revenue
Total revenue	410,897	366,052
Laboratory services
Revenue
Total revenue	21,673	42,929
Collaboration revenue
Revenue
Total revenue	$ 480,874	$ 60,764